Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria

References

• Walport Mi. Complement. N Engl J Med 2001; 344: 1058–1066.
   PubMed Web of Science ®Google Scholar
• Welch TR. Complement in glomerulonephritis. Nat Genet 2002; 31: 333–334.
   PubMed Web of Science ®Google Scholar
• Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence of antibody-and complement-mediated demyelination. Ann Neurol 1998; 43: 465–471.
   PubMed Web of Science ®Google Scholar
• Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP.Control of the complement system. Adv Immunol 1996; 61: 201–283.
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. J Immunol 1982; 129: 184–189.
   PubMed Web of Science ®Google Scholar
• Seya T, Hara T, Iwata K, et al. Purification and functional properties of soluble forms of membrane cofactor protein (MCP, CD46) of complement: identification of forms increased in cancer patients' sera. Int Immunol 1995; 7: 727–736.
   PubMed Web of Science ®Google Scholar
• Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like proteinexpressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170: 637–654.
   PubMed Web of Science ®Google Scholar
• Hebert LA. Clearance of immune complexes from the circulationof man and other primates. Am J Kidney Dis 1987; 17: 352–361.
   Google Scholar
• Nicholson-Weller A, Wang CE. Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994; 123: 485–491.
   PubMed Web of Science ®Google Scholar
• Finberg RW, White W, Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol 1992; 149: 2055–2060.
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983; 80: 5066–5070.
   PubMed Web of Science ®Google Scholar
• Pangburg MK, Schreiber RD, Muller-Eberhard HI Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983; 80: 5430–5434.
   PubMed Web of Science ®Google Scholar
• Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 1989; 74: 437–441.
   PubMed Web of Science ®Google Scholar
• Clarkson NA, Kaufman R, Lublin DM, et al. Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol 1995; 69: 5497–5501.
   PubMed Web of Science ®Google Scholar
• Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD. Coxsackie viruses Bl, B3 and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995; 69: 3873–3877.
   PubMed Web of Science ®Google Scholar
• Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M. Host-cell derived complement control proteins CD55 and CD59 are incorporated in to the virions of two unrelated enveloped viruses. Human T Cell leukemia/lymphoma virus type I (HTLV-1) and human cytomegalovirus (HCMV). J Immunol 1995; 155: 4376–4381.
   PubMed Web of Science ®Google Scholar
• Kieffer B, Driscoll PC, Campbell ID, Willis AC, van der Merwe PA, Davis Si. Three-dimensional solution structure of the extracellular region of the complement regulatory protein CD59, a new cell surface protein domain related to snake venom neurotoxins. Biochemistry 1994; 33: 4471–4482.
   PubMed Web of Science ®Google Scholar
• Meni S, Waldman H, Lachmann PI. Distribution of protecting(CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 1991; 65: 532–537.
   PubMed Web of Science ®Google Scholar
• Lachmann PI The control of homologous lysis. Immunol Today 1991; 12: 312–315.
   PubMedGoogle Scholar
• Bessler M, Hillmen P. Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemo-globinuria. Semin Hematol 1998; 35: 149–167.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Mukhina GL, Li S. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000; 114: 459–466.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253–1258.
   PubMed Web of Science ®Google Scholar
• Richards S, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal noctural hemoglobi-nuria. Cytometry 2000; 42: 223–233.
   PubMedGoogle Scholar
• Richaud-Patin Y, Perez-Romano B, Carrillo-Maravilla E, et al. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunol Lett 2003; 88: 95–99.
   PubMed Web of Science ®Google Scholar
• Douglas B, Cines MD, Victor S, Blanchette MB, Chir B. Immune thrombocytopenic purpura. New Engl J Med 2002; 346: 995–1008.
   PubMed Web of Science ®Google Scholar
• Fabris F, Steffan A, Cordiano I, et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994; 53: 232–236.
   PubMed Web of Science ®Google Scholar
• How M, Stockelberg D, Kutti J, Wadenvik H. Immunoglobulins targeting both GPIIb/IIIa and GP Ib/IX in chronic idiopathic thrombocytopenic purpura (ITP): evidence for at least two different IgG antibodies. Br J Haematol 1997; 98: 64–67.
   PubMed Web of Science ®Google Scholar
• How M, Stockelberg D, Kutti J, Wadenvik H. Fab-mediated binding of glycoprotein Ib/IX and IIb/IIIa specific antibodies in chronic idiopathic thrombocytopenic purpura. Br J Haematol 1995; 91: 944–950.
   PubMed Web of Science ®Google Scholar
• Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J, ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulat-ing antithrombopoietin antibodies. Am J Hematol 2004; 76: 205–213.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles A, León-Lloret M, Richaud-Patin Y, Llorente L, Ruiz-Arguelles GJ. Acquired deficiency of CD55 and CD59 in autoimmune hemocytopenias. In: Veskler BA. (ed) Leading edge immunology research. New York: Nova Publishers Inc., 2006; 79–94.
   Google Scholar
• Rivero Si, Diaz-Jouanen E, Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 295–305.
   PubMed Web of Science ®Google Scholar
• Drenkard C, Villa AR, Garcia-Padilla C, Perez-Vazquez ME, Alarcon-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996; 75: 88–98.
   PubMed Web of Science ®Google Scholar
• Winfield JB. Antilymphocyte autoantibodies. In: Wallace DJ, Hahn BH. (eds) Dubois' lupus erythematosus. Baltimore, MD: Williams and Wilkins, 1997; 505–515.
   Google Scholar
• van Beek J, van Meurs M, 't Hart VA, et al. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol 2005; 174: 2353–2365.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles GJ. Hipoplasias y displasias medulares. In: Ruiz-Arguelles GJ. (ed) Fundamentos de Hematologia, 3rd edition. Mexico: Editorial Médica Panamericana, 2003; 185–202.
   Google Scholar
• Young, NS. Acquired aplastic anemia. In: Schechter GP, Berliner N, Telen Mi. (eds) Hematology 2000. Washington, DC: The American Society of Hematology Education Program Book, 2000; 18–38.
   Google Scholar
• Delgado-Lamas JL, López-Karpovitch X, Marin-L6pez A, et al. Low doses of high potency antithymocite globulin (ATG) in severe aplastic anemia: experience with the Mexican ATG. Acta Haematol 1989; 81: 70–74.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arguelles GJ, Gomez Rangel, D. Long term results of the immunosuppressive treatment of patients with severe acquired aplastic anemia: a single institution study. Acta Haematologica 2003; 110: 184–187.
   PubMed Web of Science ®Google Scholar
• Sanchez-Medal L, Ruiz-Reyes G. Geographical variation in blood diseases: latin America. In: Wheatherall DJ, Ledingham JGG, Warrell DA. (eds) Oxford's textbook of medicine. Oxford: Oxford Medical, 1987; 268–70.
   Google Scholar
• Romero F. Incidencia de la anemia aplastica en Iberoamérica. In: L6pez-Borrasca A, et al. (eds) Enciclopedia Iberoamericana de Hematologia. Salamanca: Ediciones Universidad de Salamanca, 1992; 659–661.
   Google Scholar
• Benitez-Aranda H, Velez-Ruelas MA, Diaz-Cardenas S, et al. Incidence of aplastic anemia in a defined subpopulation from Mexico City. Hematology 2002; 7: 229–232.
   PubMedGoogle Scholar
• Gongora-Biachi R, Gonzalez-Martinez P, Gonzalez-Llaven J, et al. Clinical spectrum and prognostic factors in paroxysmal nocturnal hemoglobinuria in Mexico. Rev Invest Clin 1994; 46\(suppl 1): 187.
   PubMedGoogle Scholar
• Gongora-Biachi R, Gonzalez-Martinez P, Sosa-Murioz J, et al. Natural history of paroxysmal nocturnal Hemoglobinuria in adolescents, adults, and children: the Mexican experience. Sangre (Bare) 1997; 42: 171–177.
   PubMedGoogle Scholar
• Ruiz-Arguelles GJ, Ramirez Cisneros FJ, Ruiz-Argüelles A, et al. Deficiencia de proteinas de superficie ancladas por glucosil-fosfatidil-inositol en celulas de pacientes mestizos mexicanos con hipoplasia medular. Rev Invest Clin Méx 1999; 51: 5–9.
   PubMedGoogle Scholar
• Evans RS, Takahashi K, Duane RT, Payne R. Primary thrombo-cytopenic purpura and acquired hemolytic anemia: Evidence for a common etiology. AMA Arch Intern Med 1951; 1: 48–65.
   Google Scholar